Ivacaftor

Drug Profile

Ivacaftor

Alternative Names: Kalydeco; Potentiator VX-770; VX-770

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 17 May 2017 US FDA approves expansion of ivacaftor use for treatment of Cystic fibrosis (In children, In adults) associated with 33 rare gene mutations in USA
  • 28 Apr 2017 Vertex Pharmaceuticals completes the EXPAND trial for Cystic fibrosis (Combination therapy, In adolescents, In adults, In the elderly) in USA, Israel, Germany, Netherlands, Australia, Belgium, Canada, France, Italy and United Kingdom (NCT02392234)
  • 16 Mar 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease in USA (PO) (NCT03085485)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top